Chronic Lymphocytic Leukemia (CLL)

Related or Unrelated Donor

- BMT316
  - Phase II Optimizing Post-Allogeneic HCT Outcomes in Lymphoma Using Ibrutinib
  - PI: Miklos
  - Vanderbilt University

- BMT391
  - Phase II HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in Hematologic Malignancies
  - PI: Arai
  - Sponsor: National Marrow Donor Program (NMDP)

Mismatched Unrelated

- BMT146
  - Protocol for Research Database for Hematopoietic Stem Cell Transplantation and Marrow Toxic Injuries
  - PI: Miklos
  - NCI

Unrelated Donor

- BMT372
  - Phase I Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell DepletedGraft
  - PI: Meyer
  - Stanford

- BMT342
  - Phase II/III to Identify Novel Intervention to Alleviate Morbidity & Mortality After Allogeneic HCT
  - PI: Johnston
  - Fred Hutchinson

- BMT333 EXP
  - Phase III Expanded Access Omidubicel in Allogeneic Transplantation in Hematological Malignancies
  - PI: Rezvani
  - Gamida Cell

dUCB

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu